Cell And Gene Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, II, III, IV), By Indication (Oncology, CNS), By Region (Asia Pacific, North America), And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Cell And Gene Therapy Clinical Trials Market Growth & Trends
The global cell and gene therapy clinical trials market size is expected to reach USD 24.5 billion by 2030, registering a CAGR of 14.6% during the forecast period, according to a new report by Grand View Research, Inc. Cell and gene therapy (CGTs) signify the next great movement of therapeutic innovation and have resulted in the development of promising therapies around the world. Although a few of the early therapies have got marketing approval in the U.S., there are numerous promising therapies in development across the world. During the pandemic, the majority of clinical studies were focused on COVID-19. However, owing to the decline in COVID-19 cases, the market players are now shifting their focus to the development of CGTs.
For instance, in February 2022, the life sciences company, Cytiva, collaborated with NecstGen to develop gene therapies. Such collaborations are likely to promote market growth post-pandemic. The market has witnessed significant growth over the past few years, with a rise in the CGT pipeline. As reported by Global Data, in March 2021, over 2,400 CGT drugs were in the pipeline, whereas in 2020 there were over 551 CGT drugs in the clinical phase. In addition, investment is rolling into companies of various types, ranging from startups to major acquisitions by significant biopharmaceutical companies. In 2019, 19 deals of M&A worth over USD 156 billion were completed.
The largest of these was the acquisition of Celgene and its pipeline of numerous cell therapy assets for oncology treatment by Bristol-Myers Squibb for USD 74 billion. Such deals are likely to improve the market growth as CGT is gaining popularity in the treatment of life-threatening diseases. Research funding in CGT has improved in the post-pandemic period. For instance, in January 2022, researchers at the University of York received a grant of USD 3.1 million to support stem cell gene therapy research to treat sickle cell disease. In March 2022, researchers at the Indiana University School received funding of USD 12 million to develop safe gene therapy for treating hemophilia. Such investments are likely to have a positive impact on market growth.
Cell And Gene Therapy Clinical Trials Market Report Highlights
Cell And Gene Therapy Clinical Trials Market Growth & Trends
The global cell and gene therapy clinical trials market size is expected to reach USD 24.5 billion by 2030, registering a CAGR of 14.6% during the forecast period, according to a new report by Grand View Research, Inc. Cell and gene therapy (CGTs) signify the next great movement of therapeutic innovation and have resulted in the development of promising therapies around the world. Although a few of the early therapies have got marketing approval in the U.S., there are numerous promising therapies in development across the world. During the pandemic, the majority of clinical studies were focused on COVID-19. However, owing to the decline in COVID-19 cases, the market players are now shifting their focus to the development of CGTs.
For instance, in February 2022, the life sciences company, Cytiva, collaborated with NecstGen to develop gene therapies. Such collaborations are likely to promote market growth post-pandemic. The market has witnessed significant growth over the past few years, with a rise in the CGT pipeline. As reported by Global Data, in March 2021, over 2,400 CGT drugs were in the pipeline, whereas in 2020 there were over 551 CGT drugs in the clinical phase. In addition, investment is rolling into companies of various types, ranging from startups to major acquisitions by significant biopharmaceutical companies. In 2019, 19 deals of M&A worth over USD 156 billion were completed.
The largest of these was the acquisition of Celgene and its pipeline of numerous cell therapy assets for oncology treatment by Bristol-Myers Squibb for USD 74 billion. Such deals are likely to improve the market growth as CGT is gaining popularity in the treatment of life-threatening diseases. Research funding in CGT has improved in the post-pandemic period. For instance, in January 2022, researchers at the University of York received a grant of USD 3.1 million to support stem cell gene therapy research to treat sickle cell disease. In March 2022, researchers at the Indiana University School received funding of USD 12 million to develop safe gene therapy for treating hemophilia. Such investments are likely to have a positive impact on market growth.
Cell And Gene Therapy Clinical Trials Market Report Highlights
- The phase II segment accounted for the largest share in 2021 owing to a large number of therapies currently in development in phase II
- The oncology indication segment accounted for the largest share in 2021 as a high number of CGT trials are focused on the treatment of cancer
- North America dominated the global market in 2021. This is largely attributed to a large number of clinical trial activities in the U.S. and favorable government support
- Asia Pacific is expected to register the fastest CAGR over the forecast period owing to the increasing number of biotechnology companies focusing on CGTs
Table Of Contents
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation & Scope
1.1.1 Phase
1.1.2 Indication
1.1.3 Regional Scope
1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.7 List Of Secondary Sources
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective -
1.10.2 Objective -
1.10.3 Objective -
1.10.4 Objective -
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
2.2 Competitive Insights
CHAPTER 3 CELL AND GENE THERAPY CLINICAL TRIALS MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 COVID-19 Pandemic Impact On Clinical Trial Activity
3.3.1 Disrupted Clinical Trials
3.3.1.1 Troubleshooting The Manufacturing & Supply Challenges Associated To COVID-19
3.3.1.2 Other Challenges
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Growing Interest In Cell And Gene Therapy
3.4.1.2 Adoption Of New Technology In Clinical Research
3.4.1.3 Increasing Investments And R&D Funding
3.4.2 Market Restraint Analysis
3.4.2.1 Recruitment Obstacles
3.4.3 Industry Challenges
3.4.3.1 Rising Cost Of Clinical Trial
3.4.4 Major Deals & Strategic Alliances Analysis
3.4.4.1 Product/Service Launch
3.4.4.2 Merger & Acquisition
3.4.4.3 Collaboration & Partnership
3.4.4.4 Research Expansion
3.4.4.5 Service Expansion
3.4.5 Regulatory Framework
3.4.6 U.S.
3.4.7 Europe
3.4.8 China
3.4.8.1 Regulatory Challenges & Risk Of Selling Unapproved Cell Therapies
3.4.9 Japan
3.5 Cell And Gene Therapy Clinical Trials Market Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 PESTEL Analysis
CHAPTER 4 CELL AND GENE THERAPY CLINICAL TRIALS MARKET: PHASE SEGMENT ANALYSIS
4.1 Cell And Gene Therapy Clinical Trials: Market Share Analysis, 2021 & 2030
4.2 Phase I
4.2.1 Phase I Market, 2018 - 2030 (USD Million)
4.3 Phase II
4.3.1 Phase II Market, 2018 - 2030 (USD Million)
4.4 Phase III
4.4.1 Phase III Market, 2018 - 2030 (USD Million)
4.5 Phase IV
4.5.1 Phase IV Market, 2018 - 2030 (USD Million)
CHAPTER 5 CELL AND GENE THERAPY CLINICAL TRIALS MARKET: INDICATION SEGMENT ANALYSIS
5.1 Cell And Gene Therapy Clinical Trials: Market Share Analysis, 2021 & 2030
5.2 Oncology
5.2.1 Oncology Market, 2018 - 2030 (USD Million)
5.3 Cardiology
5.3.1 Cardiology Market, 2018 - 2030 (Usd Million)
5.4 CNS
5.4.1 CNS Market, 2018 - 2030 (USD Million)
5.5 Musculoskeletal
5.5.1 Musculoskeletal Market, 2018 - 2030 (USD Million)
5.6 Infectious Diseases
5.6.1 Infectious Diseases Market, 2018 - 2030 (USD Million)
5.7 Dermatology
5.7.1 Dermatology Market, 2018 - 2030 (USD Million)
5.8 Endocrine, Metabolic, Genetic
5.8.1 Endocrine, Metabolic, Genetic Market, 2018 - 2030 (USD Million)
5.9 Immunology & Inflammation
5.9.1 Immunology & Inflammation Market, 2018 - 2030 (USD Million)
5.10 Ophthalmology
5.10.1 Ophthalmology Market, 2018 - 2030 (USD Million)
5.11 Hematology
5.11.1 Haematology Market, 2018 - 2030 (USD Million)
5.12 Gastrointestinal
5.12.1 Gastrointestinal Market, 2018 - 2030 (USD Million)
5.13 Others
5.13.1 Others Market, 2018 - 2030 (USD Million)
CHAPTER 6 CELL AND GENE THERAPY CLINICAL TRIALS MARKET: REGIONAL ANALYSIS
6.1 Cell And Gene Therapy Clinical Trials: Regional Market Share
6.2 Cell And Gene Therapy Clinical Trials: Market Share Analysis, 2021 & 2028
6.3 North America
6.3.1 North America Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.3.2 U.S.
6.3.2.1 U.S. Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.3.3 Canada
6.3.3.1 Canada Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.4 Europe
6.4.1 Europe Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.4.2 U.K.
6.4.2.1 U.K. Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.4.3 Germany
6.4.3.1 Germany Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.4.4 France
6.4.4.1 France Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.4.5 Italy
6.4.5.1 Italy Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.4.6 Spain
6.4.6.1 Spain Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.5 Asia Pacific
6.5.1 Asia Pacific Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.5.2 India
6.5.2.1 India Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.5.3 Japan
6.5.3.1 Japan Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.5.4 China
6.5.4.1 China Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.5.5 Australia
6.5.5.1 Australia Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.5.6 South Korea
6.5.6.1 South Korea Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.6 Latin America
6.6.1 Latin America Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.6.2 Brazil
6.6.2.1 Brazil Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.6.3 Mexico
6.6.3.1 Mexico Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.6.4 Argentina
6.6.4.1 Argentina Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.6.5 Colombia
6.6.5.1 Colombia Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.7 MEA
6.7.1 MEA Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.7.2 South Africa
6.7.2.1 South Africa Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.7.3 Saudi Arabia
6.7.3.1 Saudi Arabia Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.7.4 UAE
6.7.4.1 UAE Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
CHAPTER 7 COMPANY PROFILES
7.1 Company Profiles
7.1.1 ICON Plc
7.1.1.1 Company Overview
7.1.1.2 Financial Performance
7.1.1.3 Product Benchmarking
7.1.1.4 Strategic Initiatives
7.1.2 IQVIA
7.1.2.1 Company Overview
7.1.2.2 Financial Performance
7.1.2.3 Product Benchmarking
7.1.2.4 Strategic Initiatives
7.1.3 LABORATORY CORPORATION OF AMERICA HOLDINGS
7.1.3.1 Company Overview
7.1.3.2 Financial Performance
7.1.3.3 Product Benchmarking
7.1.3.4 Strategic Initiatives
7.1.4 SYNEOS HEALTH
7.1.4.1 Company Overview
7.1.4.2 Financial Performance
7.1.4.3 Product Benchmarking
7.1.4.4 Strategic Initiatives
7.1.5 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
7.1.5.1 Company Overview
7.1.5.2 Financial Performance
7.1.5.3 Product Benchmarking
7.1.5.4 Strategic Initiatives
7.1.6 MEDPACE HOLDINGS, INC.
7.1.6.1 Company Overview
7.1.6.2 Financial Performance
7.1.6.3 Product Benchmarking
7.1.6.4 Strategic Initiatives
7.1.7 PPD, INC.
7.1.7.1 Company Overview
7.1.7.2 Financial Performance
7.1.7.3 Product Benchmarking
7.1.7.4 Strategic Initiatives
7.1.8 PAREXEL INTERNATIONAL Corporation
7.1.8.1 Company Overview
7.1.8.2 Financial Performance
7.1.8.3 Product Benchmarking
7.1.8.4 Strategic Initiatives
7.1.9 NOVOTECH
7.1.9.1 Company Overview
7.1.9.2 Product Benchmarking
7.1.9.3 Strategic Initiatives
7.1.10 VERISTAT, LLC
7.1.10.1 Company Overview
7.1.10.2 Product Benchmarking
7.1.10.3 Strategic Initiatives
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation & Scope
1.1.1 Phase
1.1.2 Indication
1.1.3 Regional Scope
1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.7 List Of Secondary Sources
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective -
1.10.2 Objective -
1.10.3 Objective -
1.10.4 Objective -
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
2.2 Competitive Insights
CHAPTER 3 CELL AND GENE THERAPY CLINICAL TRIALS MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 COVID-19 Pandemic Impact On Clinical Trial Activity
3.3.1 Disrupted Clinical Trials
3.3.1.1 Troubleshooting The Manufacturing & Supply Challenges Associated To COVID-19
3.3.1.2 Other Challenges
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Growing Interest In Cell And Gene Therapy
3.4.1.2 Adoption Of New Technology In Clinical Research
3.4.1.3 Increasing Investments And R&D Funding
3.4.2 Market Restraint Analysis
3.4.2.1 Recruitment Obstacles
3.4.3 Industry Challenges
3.4.3.1 Rising Cost Of Clinical Trial
3.4.4 Major Deals & Strategic Alliances Analysis
3.4.4.1 Product/Service Launch
3.4.4.2 Merger & Acquisition
3.4.4.3 Collaboration & Partnership
3.4.4.4 Research Expansion
3.4.4.5 Service Expansion
3.4.5 Regulatory Framework
3.4.6 U.S.
3.4.7 Europe
3.4.8 China
3.4.8.1 Regulatory Challenges & Risk Of Selling Unapproved Cell Therapies
3.4.9 Japan
3.5 Cell And Gene Therapy Clinical Trials Market Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 PESTEL Analysis
CHAPTER 4 CELL AND GENE THERAPY CLINICAL TRIALS MARKET: PHASE SEGMENT ANALYSIS
4.1 Cell And Gene Therapy Clinical Trials: Market Share Analysis, 2021 & 2030
4.2 Phase I
4.2.1 Phase I Market, 2018 - 2030 (USD Million)
4.3 Phase II
4.3.1 Phase II Market, 2018 - 2030 (USD Million)
4.4 Phase III
4.4.1 Phase III Market, 2018 - 2030 (USD Million)
4.5 Phase IV
4.5.1 Phase IV Market, 2018 - 2030 (USD Million)
CHAPTER 5 CELL AND GENE THERAPY CLINICAL TRIALS MARKET: INDICATION SEGMENT ANALYSIS
5.1 Cell And Gene Therapy Clinical Trials: Market Share Analysis, 2021 & 2030
5.2 Oncology
5.2.1 Oncology Market, 2018 - 2030 (USD Million)
5.3 Cardiology
5.3.1 Cardiology Market, 2018 - 2030 (Usd Million)
5.4 CNS
5.4.1 CNS Market, 2018 - 2030 (USD Million)
5.5 Musculoskeletal
5.5.1 Musculoskeletal Market, 2018 - 2030 (USD Million)
5.6 Infectious Diseases
5.6.1 Infectious Diseases Market, 2018 - 2030 (USD Million)
5.7 Dermatology
5.7.1 Dermatology Market, 2018 - 2030 (USD Million)
5.8 Endocrine, Metabolic, Genetic
5.8.1 Endocrine, Metabolic, Genetic Market, 2018 - 2030 (USD Million)
5.9 Immunology & Inflammation
5.9.1 Immunology & Inflammation Market, 2018 - 2030 (USD Million)
5.10 Ophthalmology
5.10.1 Ophthalmology Market, 2018 - 2030 (USD Million)
5.11 Hematology
5.11.1 Haematology Market, 2018 - 2030 (USD Million)
5.12 Gastrointestinal
5.12.1 Gastrointestinal Market, 2018 - 2030 (USD Million)
5.13 Others
5.13.1 Others Market, 2018 - 2030 (USD Million)
CHAPTER 6 CELL AND GENE THERAPY CLINICAL TRIALS MARKET: REGIONAL ANALYSIS
6.1 Cell And Gene Therapy Clinical Trials: Regional Market Share
6.2 Cell And Gene Therapy Clinical Trials: Market Share Analysis, 2021 & 2028
6.3 North America
6.3.1 North America Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.3.2 U.S.
6.3.2.1 U.S. Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.3.3 Canada
6.3.3.1 Canada Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.4 Europe
6.4.1 Europe Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.4.2 U.K.
6.4.2.1 U.K. Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.4.3 Germany
6.4.3.1 Germany Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.4.4 France
6.4.4.1 France Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.4.5 Italy
6.4.5.1 Italy Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.4.6 Spain
6.4.6.1 Spain Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.5 Asia Pacific
6.5.1 Asia Pacific Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.5.2 India
6.5.2.1 India Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.5.3 Japan
6.5.3.1 Japan Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.5.4 China
6.5.4.1 China Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.5.5 Australia
6.5.5.1 Australia Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.5.6 South Korea
6.5.6.1 South Korea Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.6 Latin America
6.6.1 Latin America Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.6.2 Brazil
6.6.2.1 Brazil Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.6.3 Mexico
6.6.3.1 Mexico Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.6.4 Argentina
6.6.4.1 Argentina Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.6.5 Colombia
6.6.5.1 Colombia Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.7 MEA
6.7.1 MEA Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.7.2 South Africa
6.7.2.1 South Africa Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.7.3 Saudi Arabia
6.7.3.1 Saudi Arabia Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
6.7.4 UAE
6.7.4.1 UAE Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
CHAPTER 7 COMPANY PROFILES
7.1 Company Profiles
7.1.1 ICON Plc
7.1.1.1 Company Overview
7.1.1.2 Financial Performance
7.1.1.3 Product Benchmarking
7.1.1.4 Strategic Initiatives
7.1.2 IQVIA
7.1.2.1 Company Overview
7.1.2.2 Financial Performance
7.1.2.3 Product Benchmarking
7.1.2.4 Strategic Initiatives
7.1.3 LABORATORY CORPORATION OF AMERICA HOLDINGS
7.1.3.1 Company Overview
7.1.3.2 Financial Performance
7.1.3.3 Product Benchmarking
7.1.3.4 Strategic Initiatives
7.1.4 SYNEOS HEALTH
7.1.4.1 Company Overview
7.1.4.2 Financial Performance
7.1.4.3 Product Benchmarking
7.1.4.4 Strategic Initiatives
7.1.5 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
7.1.5.1 Company Overview
7.1.5.2 Financial Performance
7.1.5.3 Product Benchmarking
7.1.5.4 Strategic Initiatives
7.1.6 MEDPACE HOLDINGS, INC.
7.1.6.1 Company Overview
7.1.6.2 Financial Performance
7.1.6.3 Product Benchmarking
7.1.6.4 Strategic Initiatives
7.1.7 PPD, INC.
7.1.7.1 Company Overview
7.1.7.2 Financial Performance
7.1.7.3 Product Benchmarking
7.1.7.4 Strategic Initiatives
7.1.8 PAREXEL INTERNATIONAL Corporation
7.1.8.1 Company Overview
7.1.8.2 Financial Performance
7.1.8.3 Product Benchmarking
7.1.8.4 Strategic Initiatives
7.1.9 NOVOTECH
7.1.9.1 Company Overview
7.1.9.2 Product Benchmarking
7.1.9.3 Strategic Initiatives
7.1.10 VERISTAT, LLC
7.1.10.1 Company Overview
7.1.10.2 Product Benchmarking
7.1.10.3 Strategic Initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 Impact of COVID-19 on new patients entering trials
Table 4 Impact of COVID-19 on other therapeutic areas
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 Impact of COVID-19 on new patients entering trials
Table 4 Impact of COVID-19 on other therapeutic areas
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Cell and gene therapy clinical trials market: Executive summary(2020)
Fig. 9 Cell and gene therapy clinical trials market: Strategy framework
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Companies with affected trials, by size
Fig. 14 Affected trials, by study phase
Fig. 15 Troubleshooting the challenges associated with COVID-19: Cell therapy development programs
Fig. 16 Troubleshooting the challenges associated with COVID-19: Cell therapy manufacturing & delivery
Fig. 17 Market driver relevance analysis (Current & future impact)
Fig. 18 Market restraint relevance analysis (Current & future impact)
Fig. 19 Porter’s five forces analysis
Fig. 20 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 21 Cell and gene therapy clinical trials market phase outlook: Segment dashboard
Fig. 22 Cell and gene therapy clinical trials market: Phase movement analysis
Fig. 23 Phase I market, 2018 - 2030 (USD Million)
Fig. 24 Phase II market, 2018 - 2030 (USD Million)
Fig. 25 Phase III market, 2018 - 2030 (USD Million)
Fig. 26 Phase IV market, 2018 - 2030 (USD Million)
Fig. 27 Cell and gene therapy clinical trials market indication outlook: Segment dashboard
Fig. 28 Cell and Gene Therapy Clinical trials market: Indication movement analysis
Fig. 29 Oncology market, 2018 - 2030 (USD Million)
Fig. 30 Cardiology market, 2018 - 2030 (USD Million)
Fig. 31 CNS market, 2018 - 2030 (USD Million)
Fig. 32 Musculoskeletal market, 2018 - 2030 (USD Million)
Fig. 33 Infectious diseases market, 2018 - 2030 (USD Million)
Fig. 34 Dermatology market, 2018 - 2030 (USD Million)
Fig. 35 Endocrine, metabolic, genetic market, 2018 - 2030 (USD Million)
Fig. 36 Immunology & inflammation market, 2018 - 2030 (USD Million)
Fig. 37 Ophthalmology market, 2018 - 2030 (USD Million)
Fig. 38 Hematology market, 2018 - 2030 (USD Million)
Fig. 39 Gastrointestinal market, 2018 - 2030 (USD Million)
Fig. 40 Others market, 2018 - 2030 (USD Million)
Fig. 41 Regional market: Key takeaways
Fig. 42 Regional market share, 2020
Fig. 43 Regional outlook, 2021 & 2030
Fig. 44 North America market, 2018 - 2030 (USD Million)
Fig. 45 U.S. market, 2018 - 2030 (USD Million)
Fig. 46 Canada market, 2018 - 2030 (USD Million)
Fig. 47 Europe market, 2018 - 2030 (USD Million)
Fig. 48 U.K. market, 2018 - 2030 (USD Million)
Fig. 49 Germany market, 2018 - 2030 (USD Million)
Fig. 50 France market, 2018 - 2030 (USD Million)
Fig. 51 Italy market, 2018 - 2030 (USD Million)
Fig. 52 Spain market, 2018 - 2030 (USD Million)
Fig. 53 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 54 India market, 2018 - 2030 (USD Million)
Fig. 55 Japan market, 2018 - 2030 (USD Million)
Fig. 56 China market, 2018 - 2030 (USD Million)
Fig. 57 Australia market, 2018 - 2030 (USD Million)
Fig. 58 South Korea market, 2018 - 2030 (USD Million)
Fig. 59 Latin America market, 2018 - 2030 (USD Million)
Fig. 60 Brazil market, 2018 - 2030 (USD Million)
Fig. 61 Mexico market, 2018 - 2030 (USD Million)
Fig. 62 Argentina market, 2018 - 2030 (USD Million)
Fig. 63 Colombia market, 2018 - 2030 (USD Million)
Fig. 64 MEA market, 2018 - 2030 (USD Million)
Fig. 65 South Africa market, 2018 - 2030 (USD Million)
Fig. 66 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 67 UAE market, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Cell and gene therapy clinical trials market: Executive summary(2020)
Fig. 9 Cell and gene therapy clinical trials market: Strategy framework
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Companies with affected trials, by size
Fig. 14 Affected trials, by study phase
Fig. 15 Troubleshooting the challenges associated with COVID-19: Cell therapy development programs
Fig. 16 Troubleshooting the challenges associated with COVID-19: Cell therapy manufacturing & delivery
Fig. 17 Market driver relevance analysis (Current & future impact)
Fig. 18 Market restraint relevance analysis (Current & future impact)
Fig. 19 Porter’s five forces analysis
Fig. 20 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 21 Cell and gene therapy clinical trials market phase outlook: Segment dashboard
Fig. 22 Cell and gene therapy clinical trials market: Phase movement analysis
Fig. 23 Phase I market, 2018 - 2030 (USD Million)
Fig. 24 Phase II market, 2018 - 2030 (USD Million)
Fig. 25 Phase III market, 2018 - 2030 (USD Million)
Fig. 26 Phase IV market, 2018 - 2030 (USD Million)
Fig. 27 Cell and gene therapy clinical trials market indication outlook: Segment dashboard
Fig. 28 Cell and Gene Therapy Clinical trials market: Indication movement analysis
Fig. 29 Oncology market, 2018 - 2030 (USD Million)
Fig. 30 Cardiology market, 2018 - 2030 (USD Million)
Fig. 31 CNS market, 2018 - 2030 (USD Million)
Fig. 32 Musculoskeletal market, 2018 - 2030 (USD Million)
Fig. 33 Infectious diseases market, 2018 - 2030 (USD Million)
Fig. 34 Dermatology market, 2018 - 2030 (USD Million)
Fig. 35 Endocrine, metabolic, genetic market, 2018 - 2030 (USD Million)
Fig. 36 Immunology & inflammation market, 2018 - 2030 (USD Million)
Fig. 37 Ophthalmology market, 2018 - 2030 (USD Million)
Fig. 38 Hematology market, 2018 - 2030 (USD Million)
Fig. 39 Gastrointestinal market, 2018 - 2030 (USD Million)
Fig. 40 Others market, 2018 - 2030 (USD Million)
Fig. 41 Regional market: Key takeaways
Fig. 42 Regional market share, 2020
Fig. 43 Regional outlook, 2021 & 2030
Fig. 44 North America market, 2018 - 2030 (USD Million)
Fig. 45 U.S. market, 2018 - 2030 (USD Million)
Fig. 46 Canada market, 2018 - 2030 (USD Million)
Fig. 47 Europe market, 2018 - 2030 (USD Million)
Fig. 48 U.K. market, 2018 - 2030 (USD Million)
Fig. 49 Germany market, 2018 - 2030 (USD Million)
Fig. 50 France market, 2018 - 2030 (USD Million)
Fig. 51 Italy market, 2018 - 2030 (USD Million)
Fig. 52 Spain market, 2018 - 2030 (USD Million)
Fig. 53 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 54 India market, 2018 - 2030 (USD Million)
Fig. 55 Japan market, 2018 - 2030 (USD Million)
Fig. 56 China market, 2018 - 2030 (USD Million)
Fig. 57 Australia market, 2018 - 2030 (USD Million)
Fig. 58 South Korea market, 2018 - 2030 (USD Million)
Fig. 59 Latin America market, 2018 - 2030 (USD Million)
Fig. 60 Brazil market, 2018 - 2030 (USD Million)
Fig. 61 Mexico market, 2018 - 2030 (USD Million)
Fig. 62 Argentina market, 2018 - 2030 (USD Million)
Fig. 63 Colombia market, 2018 - 2030 (USD Million)
Fig. 64 MEA market, 2018 - 2030 (USD Million)
Fig. 65 South Africa market, 2018 - 2030 (USD Million)
Fig. 66 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 67 UAE market, 2018 - 2030 (USD Million)
